Reliable medicine information is important when learning about Tagrisso 80 mg, a prescription anticancer medicine containing osimertinib. Information about its approved uses, dosage, safety precautions, adverse reactions and clinical benefits should be evaluated using appropriate medical and regulatory sources.
This page explains the main types of references relevant to Tagrisso and identifies authoritative publications and organizations that readers and healthcare professionals may consult. It also explains why the exact product information, publication date and applicable country matter when interpreting medical evidence.
This page is an educational guide to relevant sources. It is not a claim that every source listed has been independently reviewed for this website, and it does not replace the current approved product information for a particular market.
1. Official Prescribing Information for Tagrisso
The official prescribing information is a primary source for the medicine’s approved indications, recommended dosage, administration instructions, contraindications, warnings, precautions, adverse reactions and drug interactions.
Prescribing information may also explain patient selection criteria, molecular testing requirements, dose modifications and monitoring recommendations.
Patients and healthcare professionals should consult the current version applicable to the product and country in which the medicine is prescribed. The approved indications and instructions can change as new evidence becomes available or regulatory authorities update the product authorization.
When interpreting a prescribing document, readers should distinguish between information that applies to all patients and recommendations that apply only to a specific indication or clinical circumstance.
2. Official Patient Information Leaflet
The patient information leaflet provides instructions intended to help patients use their prescribed medicine safely. Depending on the applicable product documentation, it may describe how to take the medicine, what to do after a missed dose, how to store it and which symptoms should be reported.
The leaflet should be reviewed alongside the prescription and advice from the healthcare team. It is particularly important when the patient is uncertain about administration instructions, storage requirements or potential adverse reactions.
A leaflet supplied with a particular product may differ from documents available in another country. Patients should therefore check that the information corresponds to their actual medicine and packaging.
3. United States Food and Drug Administration
The United States Food and Drug Administration (FDA) is a regulatory authority responsible for evaluating medicines and overseeing their approved use in the United States.
FDA drug information and regulatory documents can provide details about indications, prescribing requirements, safety warnings and changes to approved labeling. These materials may also include information about clinical evidence supporting a medicine’s authorization.
FDA documentation is relevant to understanding the US regulatory status of osimertinib. However, a US authorization does not automatically establish the same indication, labeling or availability in every other country.
Readers should distinguish regulatory decisions from general medical research and should verify the authorization that applies to their location.
4. European Medicines Agency
The European Medicines Agency (EMA) provides regulatory information for medicines authorized through applicable European procedures. Its public medicine information may include product characteristics, patient leaflets, safety information and regulatory updates.
These documents can help readers understand the approved uses and precautions associated with osimertinib in the relevant European regulatory setting.
European product information should not automatically be treated as identical to US or other national labeling. Differences may occur in approved indications, wording, administration instructions or regulatory status.
5. Clinical Practice Guidelines for Lung Cancer
Clinical practice guidelines help healthcare professionals evaluate evidence and select appropriate treatment strategies for particular diseases.
Guidelines published by recognized oncology organizations may discuss molecular testing, treatment selection for EGFR-mutated NSCLC, targeted therapy, combination treatment and follow-up assessment.
Such guidelines generally consider evidence from clinical trials, expert review and other relevant research. Their recommendations may be updated as new treatments or clinical findings emerge.
Guidelines support clinical decision-making but do not replace individualized assessment. The treating oncologist must consider the patient’s diagnosis, mutation status, disease stage, treatment history and overall medical condition.
6. National Comprehensive Cancer Network
The National Comprehensive Cancer Network (NCCN) develops clinical practice guidelines for cancer care. Its lung cancer guidance addresses treatment approaches for different disease stages and molecular subtypes.
Relevant guideline material may help healthcare professionals understand how targeted therapies are considered within broader treatment pathways. Recommendations can depend on tumor characteristics, prior therapy, patient fitness and the evidence available at the time of publication.
Guideline access and the details available to individual readers may vary. Patients should ask their oncology team to explain how current recommendations relate to their own treatment plan.
7. American Society of Clinical Oncology
The American Society of Clinical Oncology (ASCO) publishes clinical guidance, educational resources and scientific material related to cancer care.
ASCO resources may address lung cancer diagnosis, molecular testing, treatment decisions, adverse-effect management and communication between patients and healthcare professionals.
These resources can help readers understand the clinical context of targeted cancer therapy. They should be interpreted according to the publication date and intended audience, because professional guidance and treatment standards can evolve.
8. Peer-Reviewed Clinical Trials
Peer-reviewed clinical trials provide important evidence about the effectiveness and safety of medicines. Trials investigating osimertinib have examined treatment outcomes in defined populations with EGFR-mutated NSCLC.
Depending on the clinical setting, trial outcomes may include progression-free survival, overall survival, disease recurrence, response rate, quality of life and adverse reactions.
Results should be interpreted in light of the study design, patient population, comparator treatment, follow-up period and limitations. A result observed in one group does not guarantee the same outcome for an individual patient or a different clinical setting.
Clinical trial publications should be considered alongside regulatory assessments and current clinical guidelines rather than in isolation.
9. The FLAURA Clinical Trial
The FLAURA trial evaluated osimertinib in patients with previously untreated advanced NSCLC harboring specified EGFR mutations. Its findings contributed to the clinical evidence supporting osimertinib in the relevant treatment setting.
When reviewing this study, readers should examine the patient eligibility criteria, comparator, measured outcomes and publication details. The results relate to the population and treatment conditions studied and should not be generalized automatically to every person with lung cancer.
The trial is one part of the wider evidence base for osimertinib, not a guarantee of individual treatment benefit.
10. The ADAURA Clinical Trial
The ADAURA trial investigated adjuvant osimertinib in eligible patients with resected EGFR-mutated NSCLC. Adjuvant treatment is intended to reduce the risk of recurrence after primary treatment, rather than to serve as a universal treatment for all lung cancers.
The trial’s results should be interpreted according to the enrolled population, treatment duration, endpoints and subsequent evidence.
Patients considering adjuvant therapy should discuss their pathology results, mutation status, recurrence risk, possible benefits and potential adverse reactions with their oncology team.
11. The LAURA Clinical Trial
The LAURA trial investigated osimertinib following definitive chemoradiation in patients with unresectable stage III NSCLC harboring specified EGFR mutations.
This clinical setting differs from first-line treatment of metastatic disease and from adjuvant treatment after surgery. The treatment indication, patient eligibility and expected objectives must therefore be evaluated separately.
Readers should consult the full clinical publication and current regulatory documentation for the applicable indication rather than assuming that findings from one treatment setting apply to another.
12. Peer-Reviewed Medical Journals
Medical journals publish clinical trial reports, systematic reviews, meta-analyses, safety studies and other research relevant to osimertinib.
When evaluating an article, readers should consider whether it has undergone peer review, when it was published, whether the study population resembles the patient being considered and whether later evidence has changed the interpretation.
A single publication should not be treated as conclusive proof of a medicine’s overall effectiveness or safety. Strong clinical conclusions generally require assessment of the broader body of evidence.
13. Molecular Diagnostic Testing References
Molecular diagnostic resources explain how EGFR mutations are identified and interpreted in lung cancer.
Appropriate testing is important because osimertinib targets specific molecular alterations. The choice of test and sample may depend on the clinical situation, the available laboratory methods and the relevant treatment indication.
Test reports should be interpreted by qualified professionals who can explain the mutation detected, the limitations of the test and how the findings influence treatment selection.
A general description of EGFR mutations does not establish that a particular patient is eligible for Tagrisso.
14. Safety and Pharmacovigilance Information
Regulatory safety communications and pharmacovigilance resources can provide updates about suspected or confirmed adverse reactions, new warnings and changes to medicine labeling.
For osimertinib, safety information is especially relevant to pulmonary toxicity, heart rhythm changes, cardiomyopathy, eye problems and other clinically important adverse reactions.
Patients should report concerning symptoms to their healthcare team rather than relying on a general reference page to determine whether a symptom is harmless.
Safety information may be revised as additional evidence becomes available. The current approved product information should be consulted for the most applicable precautions.
15. Manufacturer Product Information
Manufacturer-provided product information can help identify the active ingredient, dosage form, strength, administration instructions and approved product labeling.
However, readers should confirm that the document corresponds to the actual product and relevant country. Company information should not be used as the sole basis for determining the legitimacy of an individual package or supplier.
A product name, logo or packaging photograph does not independently prove authenticity. Questions about a specific package should be directed to a qualified pharmacist, the appropriate authorized representative or a relevant regulatory authority.
16. How to Evaluate Medical References
When reviewing a source about Tagrisso 80 mg, consider the following questions:
- Is the source an official regulator, peer-reviewed journal, recognized clinical guideline or other credible medical reference?
- Does it identify the publication date or date of the latest update?
- Does the information apply to the correct medicine, indication and patient population?
- Does it distinguish established findings from preliminary evidence or expert opinion?
- Are the conclusions consistent with current approved product information?
- Does the source explain relevant limitations and safety considerations?
These checks help reduce the risk of interpreting outdated, incomplete or misleading information as current medical guidance.
17. Limitations of Research Evidence
Clinical evidence has limitations. Studies may enroll patients who meet strict eligibility criteria and may not represent every person treated in routine clinical practice.
Results can also differ according to disease stage, molecular mutation, previous treatment, follow-up duration and the outcome being measured. A medicine’s benefit in one approved setting should not be assumed to establish benefit in all other settings.
Regulatory approval, clinical guideline recommendations and individual treatment decisions are related but distinct. Each serves a different purpose in evaluating the use of a medicine.
Conclusion
Reliable information about Tagrisso 80 mg should be based on current official prescribing information, patient leaflets, regulatory documents, recognized clinical guidelines and relevant peer-reviewed research.
Clinical trials such as FLAURA, ADAURA and LAURA contribute evidence for different osimertinib treatment settings. Their findings must be interpreted according to the populations studied and the specific treatment objectives.
Readers should use credible, current references to support informed discussions with healthcare professionals, not to replace individualized medical advice.
Medical Disclaimer: This page is an educational overview of relevant reference categories and publications. It does not constitute a complete or independently verified bibliography, an official prescribing document or a treatment recommendation. Regulatory status and clinical guidance may vary by country and change over time. Consult the current official product information and a qualified healthcare professional for decisions concerning Tagrisso 80 mg.